Focus on Drug Prices Continues Amid Uncertainty Over Potential Changes
High prescription drug prices continue to be of concern at the federal level. Despite proposed changes to drug pricing policy by the administration and HHS, industry experts question whether any significant changes will occur in the near future. Precision’s Ryan Cox and Erin Lopata weigh in on the factors contributing to the uncertainty about drug policy pricing changes.
What Do Employers Need to Know About Specialty Drugs?
Specialty drugs make up the bulk of the pharma pipeline. These drugs continue to come onto the market with higher and higher price tags, so employers should become more familiar with these therapies in order to properly manage them. Precision’s Erin Lopata and Jorge Font weigh in on the other considerations beyond cost that employers need to know for managing specialty drugs.
Bigger and Better Together: PRECISIONeffect Acquires Pascāle, Expanding Capabilities with PR and Social Media Services
Boston – August 3, 2021 – PRECISIONeffect, the industry’s only healthcare advertising agency dedicated to changing the standard of care, today announced that it has acquired Pascāle, an international healthcare communications company specializing in public relations and social media. Pascāle has an almost two-decade history of launching full-scale, creative-fueled PR and social media campaigns to drive results for healthcare clients worldwide.
A Solution Tool for Clinical Challenges in the Prognosis of Liver Injury
Several clinical scoring systems have gradually emerged for liver injury diagnosis, but certain serious inherent deficiencies currently limit their predictive value. Precision’s Anuj Mubayi and co-author Aditi Ghosh report on their first of its kind study to use mathematical modeling to provide an accurate novel prognosis method to improve tools for diagnosis and clinical management of drug-induced acute liver injury and heart-attack-influenced ischaemic hepatitis liver injury.
What does it mean to be patient centered in health economics?
With drug pricing becoming a hot-button issue in recent years, the spotlight has focused on cost effectiveness models as a means of reducing health care spending, and pharmaceutical spending in particular. Precision’s Jacquelyn Chou argues that the current cost effectiveness model is too narrow, and identifies additional elements of value that should be included to provide a better voice for patients in the science, rather than serving as a cost-containment tool.
Employers Have Variety of Approaches for High-Cost Drugs
As more high-cost drugs, including one-time gene therapies, come onto the market, employers are considering implementing a variety of contracting models to make sure their employees have access to these agents. Precision’s Jorge Font and Erin Lopata explore these innovative new approaches, as well as the challenges in executing them.
Meeting the affordability challenges posed by orphan drugs: a survey of payers, providers, and employers
As an increasing number of orphan drugs are FDA approved, health care payers, employers, and providers are attempting to strike a balance between patient access to innovative treatments and overall affordability. Precision’s Erin Lopata, Christopher Terrone and Ami Gopalan and their co-authors review the results of a PRECISIONvalue and AMCP survey with payer, provider, and employer decision makers about their experiences and activities in the orphan disease space, including tactics to manage affordability of drugs to treat orphan diseases.
Value Transformation: Observations on Performance Periods 1-5 Evaluation Report of the Oncology Care Model
The Centers for Medicare & Medicaid Services (CMS) announced another evaluation report of the Oncology Care Model (OCM) in January 2021, covering activities and results for performance periods 1 through 5 of 11. Precision’s Maureen Hennessey and Elizabeth Oyekan analyze what we’ve learned so far as they review the key findings and observations of performance periods 1 through 5.
MM&M’s Top 100 North American healthcare agencies of 2021
We are happy to announce that PRECISIONeffect and PRECISIONvalue have made the list of MM&M’s Top 100 North American healthcare agencies of 2021!
Payers Create CAR-T Approval Systems as Adoption Increases
Spurred by CMS’s decision to cover CAR-T cell therapies under Medicare, commercial payers are beginning to systematize approvals for CAR-T treatment as use of these breakthrough cancer therapies is beginning to ramp up. Precision’s Dan Danielson weighs in on factors driving authorizations now and what to expect as more CAR-T therapies are approved.
